(00:32)
 Thank you for ending your introduction, Dr. Pritt. Today, we will be discussing extended spectrum beta lactamase testing at Mayo Clinic Laboratories. But before we get started, Dr. Schuetz, could you provide our listeners with a little bit about you and your background?

(01:08)
 Thank you for sharing your background with us. Can you provide a brief overview of this testing?

 

(03:27)
 Thank you, Dr. Schuetz for this overview. Could you describe which patients should have this testing, and when should it be performed?

 

(05:22)
 This is extremely helpful; especially the ability of the testing to be utilized with investigational new drug applications. So, I got two questions for you. Could you elaborate a bit further on how this testing improves upon previous testing approaches, and are there other options on the market? If so, what makes our testing different or unique?

 

(06:46)
 I appreciate your explanation of those differences. As we conclude our interview here, could you describe for us again, the clinical action that is enabled by the results of this test via traditional patient setting or in an investigational protocol that might be underway?